Indivior Reports Strong Second-Quarter Results with Beat on Earnings and Revenue
In the second quarter, Indivior (INDV) reported Non-GAAP earnings per share of $1.15, surpassing estimates by $0.23. The company also generated revenue of $343 million, exceeding expectations by $35.45 million and marking a 13.6% year-over-year increase. A key highlight was the record quarterly net revenue from SUBLOCADE® reaching $253 million in Q2'26, reflecting a 21% growth compared to last year. As of June 30, 2026, Indivior reported serving over 545,000 patients. The strong performance underscores the company's growing market presence and successful product adoption.
Tickers: $INDV
Topics: pharmaceuticals revenue_growth SUBLOCADE®